Poolbeg Pharma plc, a clinical-stage biopharmaceutical company, has announced that the US Patent Office will grant its US Immunomodulator I patent application. The patent covers POLB 001, a selective p38 MAP kinase inhibitor, and other similar inhibitors for treating patients at risk of severe influenza and hypercytokinemia (cytokine storm), a condition often associated with severe influenza cases. POLB 001, which is ready for Phase II trials, demonstrates strong therapeutic potential across various diseases.
This development adds significant strength to Poolbeg’s intellectual property (IP) portfolio. The company already holds patents for using p38 MAP kinase inhibitors in severe influenza and POLB 001 in hypercytokinemia treatment. Additionally, Poolbeg has filed further complementary patent applications, focusing on extending coverage to cytokine release syndrome caused by cancer immunotherapies. This strategic approach to IP development is central to enhancing the value and commercial appeal of POLB 001, making it an attractive proposition for potential partnerships.
Dr Jeremy Skillington, Poolbeg Pharma’s Chief Executive Officer, highlighted the importance of this patent in solidifying the company’s IP position. He stated that a strong IP foundation is essential for creating value in biopharma. Each new patent enhances asset protection and boosts the commercial potential of POLB 001 for future collaborations. He reaffirmed the company’s commitment to addressing critical medical needs through high-value programmes and partnerships aimed at advancing and commercialising Poolbeg’s innovative assets.
This patent grant not only secures a critical milestone for Poolbeg but also reinforces its position in the biopharmaceutical industry. With a focus on expanding its IP portfolio and building valuable collaborations, Poolbeg continues to make strides in delivering innovative solutions for diseases with unmet medical needs.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
